Pharmaceuticals Hong Kong

Hong Kong Radiopharmaceuticals Market Analysis, 2024–2034

Updated Reviewed by Chandani Patel

Hong Kong Radiopharmaceuticals Market Industry Trends and Forecast to 2034: Segmented by (Type, Isotope, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034

Overview

Market Dashboard

Hong Kong · 2024–2034 · placeholder estimates

Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.

Estimate 2024 $12.9 Mn Placeholder estimate
Estimate 2025 $14.3 Mn 0.2% of the global market
Projected 2034 $37.3 Mn 160% Adds $22.9 Mn over 9 forecast years
CAGR 2025–2034 11.2% Faster than 61% of 180 Pharmaceuticals markets here
Key players 6 +1
  • Hong Kong is 0.16% of the global market.
  • In APAC, the largest is China at $813.1 Mn.
  • Fastest growing: India at 12.8% a year.
  • Hong Kong ranks 8th of 10 by size in APAC.

Market size projection

Hong Kong

Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.

Value added each year

$22.9 Mn total, 2026–2034

Year-by-year market size, 2024–2034
Radiopharmaceuticals Market market size by year, Hong Kong
YearMarket sizeChange that yearSince 2025
2024 (estimate) $12.9 Mn — —
2025 (base) $14.3 Mn +$1.4 Mn —
2026 (forecast) $16.0 Mn +$1.6 Mn +11.2%
2027 (forecast) $17.7 Mn +$1.8 Mn +23.7%
2028 (forecast) $19.7 Mn +$2.0 Mn +37.5%
2029 (forecast) $21.9 Mn +$2.2 Mn +52.9%
2030 (forecast) $24.4 Mn +$2.5 Mn +70%
2031 (forecast) $27.1 Mn +$2.7 Mn +89.1%
2032 (forecast) $30.2 Mn +$3.0 Mn +110.2%
2033 (forecast) $33.5 Mn +$3.4 Mn +133.8%
2034 (forecast) $37.3 Mn +$3.8 Mn +160%

Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.

Report snapshot

Hong Kong Radiopharmaceuticals Market Analysis at a glance
Market size, 2025$14.3 Mn placeholder estimate
Forecast, 2034$37.3 Mn placeholder estimate
Growth (CAGR), 2025–203411.2% placeholder estimate
Years2024 historical · 2025 base year · 2026–2034 forecast
SegmentsType, isotope and end user (see all)
Key playersNovartis AG, Bayer AG, Lantheus Holdings, Curium, Telix Pharmaceuticals and 1 more (see all)
Regulator in Hong KongDrug OfficeSource: Drug Office, Department of Health. Checked 14 Nov 2026.
Active clinical trials1 in Hong KongSource: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Hong Kong. Retrieved 12 Nov 2026.
FormatsPDF, PPTX, XLSX

Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.

The Hong Kong Radiopharmaceuticals Market Analysis Executive Summary

Radiopharmaceuticals are drugs that carry a radioactive element to image or kill cancer cells.

Key segments of the radiopharmaceuticals market include type (Diagnostic and Therapeutic) and isotope (Lutetium-177, Actinium-225 and Fluorine-18).

Bar chart: Hong Kong Radiopharmaceuticals market size, 2024–2034, placeholder estimates. $12.9 Mn in 2024, $14.3 Mn in 2025 and $37.3 Mn in 2034, 11.2% CAGR.
Hong Kong Radiopharmaceuticals market size, 2024–2034. Placeholder estimates; researched figures come with the full report. Source: Acuitas Health Analytics.

Hong Kong Radiopharmaceuticals Market Dynamics

Market Growth Drivers

Rising cancer cases, earlier detection, precision medicine and a strong pipeline of targeted and immune therapies are driving the radiopharmaceuticals market. Faster approvals and new combinations are improving survival.

Opportunity

Biomarker-led treatment, earlier lines of therapy and expansion into emerging markets offer strong growth for the radiopharmaceuticals market.

Market Restraints

High treatment costs, drug resistance, side effects and unequal access to cancer centres hold back the radiopharmaceuticals market, especially in low- and middle-income countries.

Competitive Landscape for Radiopharmaceuticals Market in Hong Kong

The radiopharmaceuticals market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.

Key Players

Healthcare Policies and Regulatory Landscape for Radiopharmaceuticals Market in Hong Kong

Radiopharmaceuticals in Hong Kong: rules, payment and research

Pharmaceutical products must be registered with the Pharmacy and Poisons Board before sale, through the Drug Office of the Department of Health.⁠[1] Public hospitals and clinics, run by the Hospital Authority, are heavily subsidised by the government.⁠[2] ClinicalTrials.gov lists 1 study on Radiopharmaceuticals that is recruiting, active or about to start in Hong Kong.⁠[3]

[1] Drug Office, Department of Health. Checked 14 Nov 2026.

[2] Hospital Authority. Checked 14 Nov 2026.

[3] ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Hong Kong. Retrieved 12 Nov 2026.

Policy changes and Reimbursement scenario

Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for radiopharmaceuticals. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in Hong Kong.

Beyond the market numbers

Research, trials and patients

What doctors and scientists are doing in Radiopharmaceuticals right now, from free public sources.

Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov, World Bank. Fetched 12 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.

Public data, with sources

Radiopharmaceuticals in context

Hong Kong compared

  • People aged 65 and over: 23.7% of people (2025). World: 10.4% of people (2025). 2nd highest of the 16 countries we cover in APAC.[1]

[1] World Bank Open Data, People aged 65 and over (% of people). Retrieved 18 Nov 2026.

Free data on this topic

Quick answers

Frequently asked questions

How big is the Radiopharmaceuticals market in Hong Kong?
Placeholder estimate: about $14.3 Mn in 2025, rising to about $37.3 Mn by 2034. These are early estimates, not researched figures; the researched values come with the full report.
How fast is the Radiopharmaceuticals market in Hong Kong growing?
Placeholder estimate: about 11.2% a year (CAGR, 2025–2034). The researched growth rate comes with the full report.
What segments does the Radiopharmaceuticals market report cover?
The report splits the market by type (Diagnostic, Therapeutic), isotope (Lutetium-177, Actinium-225, Fluorine-18, Technetium-99m and more) and end user (Hospitals, Specialty Clinics, Retail Pharmacies, Online Pharmacies).
Who are the key players in the Radiopharmaceuticals market?
Key players include Novartis AG, Bayer AG, Lantheus Holdings, Curium, Telix Pharmaceuticals and GE Healthcare.
What is driving the Radiopharmaceuticals market?
Rising cancer cases, earlier detection, precision medicine and a strong pipeline of targeted and immune therapies are driving the radiopharmaceuticals market. Faster approvals and new combinations are improving survival.
Who regulates Radiopharmaceuticals in Hong Kong?
Pharmaceutical products must be registered with the Pharmacy and Poisons Board before sale, through the Drug Office of the Department of Health. Source: Drug Office, Department of Health. Checked 14 Nov 2026.
How is healthcare paid for in Hong Kong?
Public hospitals and clinics, run by the Hospital Authority, are heavily subsidised by the government. Source: Hospital Authority. Checked 14 Nov 2026.
How many clinical trials on Radiopharmaceuticals are running in Hong Kong?
1 study is recruiting, active or about to start in Hong Kong, according to ClinicalTrials.gov. Source: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Hong Kong. Retrieved 12 Nov 2026.
How much research is published on Radiopharmaceuticals?
PubMed lists 2,809 papers on Radiopharmaceuticals added since January 2021, worldwide. Source: PubMed, Papers added since 1 January 2021 matching this market. Retrieved 12 Nov 2026.
Back to Catalogue

Related Pharmaceuticals reports in Hong Kong

See all

Related on oncology

See the topic